A Study of LY3214996 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3214996

Drug: [14C]-LY3214996

Study type

Interventional

Funder types

Industry

Identifiers

NCT04033341

17199

I8S-MC-JUAD (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to six weeks.

Enrollment

6 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly health males
Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion criteria

Females
Male participants sexually active with a pregnant partner
Are currently enrolled in a clinical study or have participated, within the last 30 days, in a clinical study
Have participated in a radiolabeled drug study within the previous 4 months
Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
Have a history of Gilbert's syndrome
Have history or presence of psychiatric disorders
Show evidence of human immunodeficiency virus (HIV) infection
Show evidence of hepatitis C
Show evidence of hepatitis B